科研动态期刊摘要
TROP2归一化膜比率作为datopotamab deruxtecan治疗非小细胞肺癌临床结局的预测指标
Nature Medicine · 2026-11-11
摘要
《自然·医学》,在线发表于2026年11月11日;doi:10.1038/s41591-026-04716-9 本研究开发并验证了一种计算病理学生物标志物——TROP2归一化膜比率,该指标可量化TROP2的亚细胞定位,并预测无可用靶向基因组变异的非鳞状非小细胞肺癌患者接受datopotamab deruxtecan治疗后无进展生存期和总生存期的改善。
English
Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04716-9 This work developed and validated a computational pathology biomarker—the TROP2 normalized membrane ratio—that quantifies subcellular TROP2 localization and predicts improved progression-free and overall survival with datopotamab deruxtecan in patients with nonsquamous non-small-cell lung cancer lacking actionable genomic alterations.